• Saadia Fawad


Background: Recurrent pregnancy loss is a major health problem effecting 1‒2% of women ofreproductive age. Its causes range from chromosomal abnormalities to endocrinological factors andthrombophilia related factors. Treating thrombophilias especially antiphospholipid syndrome with lowdose aspirin and low molecular weight heparin improves foetal outcome. This study will add local datato already existing knowledge. Method: Sixty selected patients from gynaecology OPD of AeroHospital with clinical and/or serological findings of antiphospholipid syndrome from February 2009 toJanuary 2011 were given aspirin 75 mg once daily and enoxaparine 40 mg subcutaneously once dailyfrom 6–8 weeks to 35 and 37 weeks respectively. Results: Ninety-three percent of patients achievedlive birth. Out of these 75% patients delivered at term and 18% had preterm delivered. Four (7%) hadearly pregnancy loss and only one had early neonatal death due to extreme prematurity. None ofpatients experienced any major hemorrhagic complications. Conclusion: Use of low dose aspirin andlow molecular weight heparin is safe in pregnancy and improve foetal outcome in patients withrecurrent pregnancy loss due to antiphospholipids syndrome.Keywords: Recurrent pregnancy loss, Antiphospholipid syndrome, low molecular weight heparin


Clifford K, Rai R. Wason H, Regon L. An informative protocol

for the investigation of recurrent miscarriage, preliminary

experience of 500 consecutive cases. Human Reprod


Hatasake HH. Recurrent miscarriage:epidemiologic factors,

definitions and incidence. Clin Obstet Gynecol 1994;37:625–34.

Brenner B, Sarig Gy, Weiner Z, Younis J, Blumenfeld Z, Lanir

N. Thrombophilic polymorphisms are common in women with

fetal loss without apparent cause. Thromb Haemost 1999;82:6–9.

Triplett DA, Harris EN. Antiphopholipid Anti bodies and

reproduction. Am J Reprod Immunol1989;21:123–31.

Levine JS, Branch DW, Raich J. The antilospholipid syndrome N

Engl J Med 2002:346:752–63.

Roubey RAS. Immunology of Antiphospholipid syndrome.

Arthritis Rheum1996;39:1444–54.

Wilson W, Gharavi A, Koike T, Lockshin MD, Branch DW,

Piette JC, et al. International consenses statement on preliminary

classification criteria for definite antiphospholipid syndrome:

report on an international workshop. Arthritis Rheum


Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL,

Cervera R, et al. International Consenses statement on an update

of classification criteria for definite anti phospholipid syndromes

(APS). J Thromb Haemost 2006;4:295‒306.

Baker WF Jr, Bick RL. The clinical spectrum of

Antiphospholipid syndrome. Hematol Oncol Clin N Am


Hughes GR, Khamashta MA. Seronegative anti phospholipid

syndrome. Ann Rheum Dis 2003;62:1127.

Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y,

Camps MT, et al. Anti phospholipid syndrome: clinical and

immunologic manifestation and patterns of disease expression in

a chort of 1000 patients. Arthritis Rheum 2002;46:1019–27.

Mo D, Saravelos S, Metwally M, Makris M, Li TC. Treatment of

recurrent miscarriage and anti phospholipid syndrome with low

dose Enoxaparin and Aspirin. Reprod Biomed online


Berg TG. Antiphospholipid antibody syndrome and pregnancy.

Available from: http://emedicine.Medscape.Com/article/


J Ayub Med Coll Abbottabad 2010;22(3)

Ensom MH, Stephenson MD. Pharmaco kinetics of low

molecular weight Heparin and unfractionated Heparin in

pregnancy. J Soc Gynocol Investig 2004;11:377–83.

Stephenson MD, Ballem PJ, T sang P, Purkiss S, Houlihan E,

Enson MH. Treatment of Antiphospholipid antibody syndrome

(APS) in pregnancy: a random pilot total comparing low

molecular weight Heparin to unfractionated Heparin. J Obstet

Gynacol Can 2004;26:729–34.

Shannon M. Bates, Ian A. Grear, Jack Hirsh, Jerry S. Ginsberg

use of antithrombotic agents during pregnancy. Chest J


Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis JS.

Gestational outcome in Thrombophilic women with Recurrent

Pregnancy loss Treated by Enoxaparin. Thromb Haemost